Publications by authors named "W J M Dewilde"
Article Synopsis
- * Colchicine is currently the only anti-inflammatory medication showing promise for CAD, but more research is needed to fully understand its effectiveness and safety as a primary treatment option.
- * The COL BE PCI trial aims to evaluate the efficacy of colchicine versus placebo in 2,770 patients post-percutaneous coronary intervention (PCI), focusing on major cardiovascular events as the primary outcome of the study.
Background: Incomplete revascularization (ICR) has been associated with a worse prognosis after a percutaneous coronary intervention (PCI). In NSTEMI patients with multivessel disease (MVD) however, the benefit of a complete revascularization (CR) remains unclear.
Methods: Patients presenting with an NSTEMI and MVD were selected from the global e-ULTIMASTER registry and grouped according to completeness of revascularization at index hospitalization discharge.
Article Synopsis
- The optimal management of patients with atrial fibrillation (AF) requiring oral anticoagulation (OAC) during percutaneous coronary intervention (PCI) is debated, with current guidelines suggesting a temporary triple therapy regimen that includes aspirin, which raises bleeding risks.
- A new study, the WOEST-3 trial, seeks to compare a 30-day dual antiplatelet therapy (DAPT) strategy that temporarily omits OAC against guideline-directed therapy post-PCI for AF patients, aiming to reduce bleeding without sacrificing efficacy.
- With a sample of 2,000 patients, the trial will evaluate the rates of major bleeding and adverse ischemic events, making it the first randomized controlled trial to explore the omission of OAC
Article Synopsis
- A significant number of patients undergoing percutaneous coronary intervention (PCI) have few or no standard modifiable cardiovascular risk factors (SMuRFs), such as hypertension, diabetes, hypercholesterolemia, and smoking.
- The study analyzed patients based on how many SMuRFs they had and found that as the number of SMuRFs increased, the risk of target lesion failure (TLF) also rose significantly.
- Patients without SMuRFs had better outcomes, but there's a need for further research to improve treatment strategies for the majority who do have risk factors.
Background: Evidence-based recommendations for antithrombotic treatment in patients who have an indication for oral anticoagulation (OAC) after transcatheter edge-to-edge mitral valve repair (TEER) are lacking.
Aims: To compare bleeding and thrombotic risk for different antithrombotic regimens post-TEER with MitraClip in an unselected population with the need for OACs.
Methods: Bleeding and thrombotic complications (stroke and myocardial infarction) up to 3 months after TEER with mitraclip were evaluated in 322 consecutive pts with an indication for OACs.